RGC — Regencell Bioscience Holdings Balance Sheet
0.000.00%
Last trade - 00:00- $797.04m
- $789.08m
- 41
- 21
- 80
- 44
Annual balance sheet for Regencell Bioscience Holdings, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.387 | 0.059 | 16.4 | 11.6 | 7.96 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.387 | 0.067 | 16.4 | 11.6 | 8.11 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.108 | 0.082 | 1.46 | 0.892 | 0.227 |
| Other Long Term Assets | |||||
| Total Assets | 0.514 | 0.34 | 18 | 12.6 | 8.44 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.16 | 4.34 | 0.578 | 0.607 | 0.194 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.16 | 4.34 | 0.953 | 0.591 | 0.22 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2.65 | -4 | 17.1 | 12 | 8.22 |
| Total Liabilities & Shareholders' Equity | 0.514 | 0.34 | 18 | 12.6 | 8.44 |
| Total Common Shares Outstanding |